Organizing Committee Members - ONCOLOGY 2023
Qian Tao
Professor
The Chinese University of
Hong Kong
Qian Tao(Biography)
Prof. Tao obtained his PhD from the University of Hong Kong and did his postdoc training in Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine. He was appointed as Assistant Professor in Johns Hopkins School of Medicine in 1999, and later Associate Professor and Full Professor (2008) in the Chinese University of Hong Kong. He leads the Cancer Epigenetics Laboratory in the State Key Laboratory of Oncology in South China, Faculty of Medicine, The Chinese University of Hong Kong. Prof Tao’s group has established the CpG methylomes of common tumors in Hong Kong including nasopharyngeal, esophageal, lung, digestive cancers and lymphomas; identified multiple novel TSGs (e.g. PCDH10, RASAL1, ZNF382, BLU, ZNF545, BCL6B, JPH3, DLEC1, etc) and characterized their molecular functions in cell signaling and tumorigenesis; and also developed promising epigenetic biomarkers and therapeutics. He has published 160 papers (total citations: 8500; h-index: 55) on cancer epigenetics and cancer biology in international journals, including PNAS, Lancet, JCO, Cancer Res, Blood, Gut, Hepatology and Theranostics, and 4 book chapters on epigenetics. He is an external reviewer for multiple scientific journals and an academic Editor for several journals. He also serves as a grant review panel member for China Natural Science Foundation (NSFC) and a reviewer for several other agents including AICR, Wellcome Trust, MRC/UK, Dutch Cancer Society, Singapore National Medical Research Council, and China Ministry of Science and Technology (MOST). He has been a vice-President for the international Epigenetics Society (http://epigeneticssocietyint.com/) since 2008.
Qian Tao(Research Area)
Cancer epigenomics: identification of novel tumor suppressor genes (TSG) and their functional/mechanistic characterization in tumorigenesis ; Identification of epigenetic modifier genes involved in aberrant CpG methylation and chromatin-remodeling in tumors; Development of epigenetic biomarkers and epigenetic therapeutics; Epigenetic regulation of EBV genes and EBV-modulated aberrant epigenetic programming in EBV pathogenesis
David I Smith
Doctor
Mayo Clinic Rochester
USA
David I Smith(Biography)
David I Smith received his B.S. In Mathematics and Molecular Biology from the University of Wisconsin in Madison. He then went on to get his Ph.D. In Biochemistry, also at the UW Madison in 1978. His first faculty position was at Wayne State University in Detroit. For the past 22 years he has been a Professor in the Department of Laboratory Medicine and Pathology at the Mayo Clinic. He is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. His laboratory studies genome inability and the common fragile sites and their role in cancer development. His laboratory also studies the different ways the human papillomavirus is involved in the development of different cancers. The tools that Dr. Smith’s laboratory uses to address these questions is massively parallel next generation sequencing.
David I Smith(Research Area)
Current Projects :- Oropharyngeal cancer, Long noncoding RNA.
Reema Al Hayek
Consultant
King Fahd Specialist Hospital Dammam
Saudi Arabia
Reema Al Hayek(Biography)
Reema Al Hayek(Research Area)
Pediatric Oncology-Hematology